Predict your next investment

Exo Therapeutics company logo
HEALTHCARE | Drug Discovery
exo-therapeutics.com

See what CB Insights has to offer

Founded Year

2018

Stage

Series B | Alive

Total Raised

$103M

Last Raised

$78M | 4 mos ago

About Exo Therapeutics

Exo Therapeutics is a small molecule drug discovery and development company with technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.

Exo Therapeutics Headquarter Location

480 Arsenal Way

Watertown, Massachusetts, 02472,

United States

Latest Exo Therapeutics News

Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer

Jan 18, 2022

January 18, 2022 07:00 AM Eastern Standard Time WATERTOWN, Mass.--( BUSINESS WIRE )-- Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer. “It is my pleasure to welcome Antonio to Exo and work with him as we continue to progress our programs,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Antonio is an outstanding leader with broad experience gained at both small and large biopharmaceutical companies. He will be an invaluable addition to our team as we advance our pipeline toward the clinic in service to patients suffering from serious diseases.” “The reprogramming of proteins via exosites is a unique drug development approach with great potential and compelling early data. I’m excited to lead the discovery and development of these novel agents,” said Dr. Gualberto. “I look forward to working with the extraordinary team at Exo on expanding a pipeline of drugs addressing multiple indications with a high unmet medical need.” “I have had the pleasure of working with Antonio previously and have seen his impactful contributions firsthand,” said Thilo Schroeder, PhD, Board of Directors member of Exo Therapeutics. “As Exo continues to rapidly strengthen its ExoSightTM platform, it is a perfect time to add someone with Antonio’s superb R&D expertise and ability to advance our programs.” Dr. Gualberto brings over 20 years of drug development experience, spanning candidate selection to registration and market access. Before joining Exo, Dr. Gualberto served as CMO at H3 Biomedicine, a subsidiary of Eisai Ltd., where he led the development of the ERα inhibitor H3B-6545 and the SF3B1 modulator H3B-8800, among others. Prior to H3B, he was CMO and co-founder at Kura Oncology where he led the clinical proof-of-concept of farnesyl transferase inhibitors. Prior to Kura, he held positions of increasing responsibility at EMD Serono, Takeda and Pfizer where he contributed to the development of erlotinib, tremelimumab, neratinib and brentuximab vedotin. Dr. Gualberto received his MD and PhD degrees from the University of Seville in Spain, trained at the University of North Carolina at Chapel Hill and the Berkeley National Laboratory, and held academic faculty positions at Case Western Reserve University and Brown University. About Exo Therapeutics Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Exo Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Exo Therapeutics in 1 CB Insights research brief, most recently on Jan 19, 2021.

Expert Collections containing Exo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exo Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

818 items

Exo Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exo Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.